InvestorsHub Logo
Followers 6
Posts 1400
Boards Moderated 0
Alias Born 08/24/2014

Re: None

Wednesday, 11/08/2017 9:43:48 AM

Wednesday, November 08, 2017 9:43:48 AM

Post# of 48316
The takeaway from the Adam F. article is: good PISCES results for Oncosec will override the INCYTE results because Oncosec PISCES trial is targeting the checkpoint failure population....more conclusive data. Good results from PISCES and we will see an INCYTE type of valuation next year. LOOKING GOOD!